ABSI — Absci Corporation
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 156
- Website: https://www.absci.com
Latest SEC filings for ABSI
- 10-Q — 2026-08-11
- 8-K — 2026-08-11
- 8-K — 2026-06-24
- 424B5 — 2026-06-24
- 8-K — 2026-06-24
- 8-K — 2026-06-05
- 10-Q — 2026-05-07
- 8-K — 2026-05-07
- SCHEDULE 13D/A — 2026-04-15
- SCHEDULE 13G/A — 2026-03-26
Latest ABSI news
- — Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026 (globenewswire.com)
- — Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)
- — Global Drug Discovery AI Tools Market - Strategic Forecast 2026-2032 | Generative AI, Cloud Platforms, and Integrated R&D Workflows Create New Growth Opportunities (GlobeNewswire Inc.)
Educational tool only — not investment advice.